Bimekizumab demonstrated a favorable safety profile for the long-term treatment of axSpA and PsA, with rates of TEAEs remaining stable over time.

The median time to treatment initiation is increasing across cancer types, and this appears to be driven by an increase in stage I cancer diagnoses, data suggest.

Adolescents with alopecia areata experience a greater effect on quality of life than adults when experiencing 50% or greater scalp hair loss.

Adults with plaque psoriasis aged 65 years and older had similar responses to IL-17 and IL-23 inhibitors to that of younger adults.